02:26 PM EDT, 05/07/2026 (MT Newswires) -- Novartis ( NVS ) said Thursday it started construction on a new radioligand therapy manufacturing facility in Denton, Texas, as part of the company's broader $23 billion US investment plan.

The company said the Texas facility will become its fifth radioligand therapy manufacturing site in the US and is expected to begin operations in 2028, supporting production of personalized cancer therapies.

The company said the project is part of its plan to expand US manufacturing and research operations over five years.

Price: 145.47, Change: -2.89, Percent Change: -1.95